Uterine fibroids (leiomyomas) are present in> 75% of women and can cause serious
morbidity. They are by far the leading cause of hysterectomy. Fibroids are a complex mixture …

Background Endometriosis is a common cause of pelvic pain in women, for which current
treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone …

(1) Background: Uterine fibroids are the most common form of benign uterine tumors,
causing heavy menstrual bleeding (HMB), pelvic pain, infertility and pressure symptoms …

Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Uterine fibroids (UFs), also known as leiomyomas, are benign tumors of the myometrium
affecting over 70% of women worldwide, particularly women of color. Although benign, UFs …

Uterine fibroid (UF) driver mutations in Mediator complex subunit 12 (MED12) trigger
genomic instability and tumor development through unknown mechanisms. Herein, we show …

Cucurbitacin B (CuB) is a potent but toxic anticancer natural product. Herein, we designed
and synthesized 2-OH-and 16-OH-modified CuB derivatives to improve their antitumor …

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as
norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of …

OBJECTIVE: In the LIBERTY 1 and LIBERTY 2 placebocontrolled trials, once-daily relugolix
combination therapy reduced menstrual blood loss volume and pain in women with heavy …

Leiomyomas, or uterine fibroids as they are commonly known, are mostly seen in women of
reproductive age. However, they can go undetected in most women, and approximately 25 …